Cutaneous Leishmaniasis
Conditions
Keywords
Leishmaniasis, Subunit Vaccine, Prevention, T cell
Brief summary
This study will evaluate the safety and immunogenicity of the Leish-111f + MPL-SE vaccine in adult subjects who have no evidence of previous exposure to the Leishmania parasite.
Detailed description
Cutaneous leishmaniasis is a disfiguring disease that can progress to mucosal leishmaniasis, a more serious and possibly fatal form of Leishmania disease. All available medical therapies require weeks of treatment and cause significant toxicity. It appears that Leishmania infections can be eliminated or prevented by T helper 1 immune responses. These findings argue that a vaccine that generates a T helper 1 response against the parasite will prevent the infection and disease. This is a phase 2, randomized, double blind, placebo-controlled study to evaluate the safety, tolerability and immunogenicity in Montenegro skin test (MST)-negative healthy adults of an investigational vaccine being developed for the prophylaxis of cutaneous leishmaniasis. The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f, 10 μg) together with the adjuvant MPL-SE (25 μg). In addition, the safety and immunogenicity of the vaccine will be compared to that of the Leish-111f protein (10 μg) given alone. The vaccine, Leish-111f protein alone or placebo will be given to each study subject three times at 4 week intervals.
Interventions
BIOLOGICALLeish-111f + MPL-SE vaccine
Sponsors
Bill and Melinda Gates Foundation
Access to Advanced Health Institute (AAHI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Must have negative Montenegro skin test (0 mm) * Must be in good general health with normal lab values * Negative for HIV, hepatitis B and C
Exclusion criteria
* History of leishmaniasis or exposure to Leishmania vaccine or MPL-SE * Nursing or pregnant female
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | — |
| Dose-limiting toxicities: hematology and serum chemistry evaluations at Screening, Days 7, 35, 63, 84 | — |
| T-cell IFN-γ response to the Leish-111f protein: immunology evaluations at Days 0, 84, 168 | — |
Secondary
| Measure | Time frame |
|---|---|
| T-cell IL-5 response to the Leish-111f protein | — |
| Antibody responses to the Leish-111f protein | — |
| Skin test reactivity to the Leish-111f protein at Days 84, 168 | — |
Countries
Colombia
Outcome results
None listed